Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Carcinoid Tumor 2Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Carcinoma 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Everolimus 6Sunitinib 3Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Injections 2recombinant interferon alpha 2b-like protein 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1fludarabine phosphate 1cabozantinib 1batifiban 1abemaciclib 1X-Rays 1Sorafenib 1Phantoms, Imaging 1PM 01183 1Oxaliplatin 1Leucovorin 1Interleukin-13 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cryotherapy 1Biopsy 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × pasireotide × NET × Clear all
NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡